Silexion Therapeutics Corp announced groundbreaking preclinical data showing up to 97% inhibition rates in pancreatic cancer cells and nearly 90% in colorectal cancer cells. These findings demonstrate SIL204’s potential as a pan-KRAS therapeutic for various cancer types and mutations. The Company plans to initiate a Phase 2/3 clinical trial in Q2 2026 to investigate SIL204 for treating KRAS-driven solid tumor cancers. Additionally, recent results in lung cancer cell lines validate the innovative delivery system used by Silexion. These developments indicate the broad applicability of SIL204 in addressing aggressive KRAS-driven cancers, highlighting its potential against multiple variants.

Read more at GlobeNewswire: Silexion Therapeutics Announces New Preclinical Data